13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
67 檔
29.5%
According to the latest 13F quarterly dataset, Eversept Partners, LP managed an equity portfolio of $1.9B at the end of Q3 2024, spanning 67 distinct U.S. exchange-listed positions.
In Q3 2024, Eversept Partners, LP adopted a defensive or profit-taking posture, trimming 32 positions and completely liquidating 17 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 11.36% | -3.89% | +16.99% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 8.34% | -3.49% | -12.61% | |
| 3 | NTRA | Natera Inc | Stock-Healthcare | 7.57% | -1.58% | -25.85% | |
| 4 | VERA | Vera Therapeutics Inc | Stock-Other | 6.21% | +0.32% | +0.34% | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 5.45% | +0.55% | -5.73% | |
| 6 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 5.41% | -0.38% | +13.61% | |
| 7 | RVTY | Revvity Inc | Stock-Healthcare | 4.11% | +0.09% | +4.01% | |
| 8 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 3.99% | — | -48.17% | |
| 9 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 3.99% | — | -31.48% | |
| 10 | CYH | Community Health Systems Inc | Stock-Other | 3.65% | +0.01% | +9.19% | |
| 11 | TECH | Bio-techne CORP | Stock-Healthcare | 3.63% | -0.28% | +22.20% | |
| 12 | HCA | Hca Healthcare Inc | Stock-Healthcare | 3.59% | +0.01% | -4.72% | |
| 13 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.21% | -0.17% | -44.36% | |
| 14 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 2.36% | -3.67% | EXIT | |
| 15 | ZIMV | Zimvie Inc | Stock-Other | 2.25% | — | +169.75% | |
| 16 | HQY | Healthequity Inc | Stock-Healthcare | 1.79% | -0.23% | EXIT | |
| 17 | RGEN | Repligen CORP | Stock-Healthcare | 1.67% | -0.65% | -15.80% | |
| 18 | VTRS | Viatris Inc | Stock-Healthcare | 1.37% | — | +29.87% | |
| 19 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.37% | +0.37% | NEW | |
| 20 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.32% | +0.46% | -10.76% | |
| 21 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.29% | +0.23% | +3.17% | |
| 22 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.08% | +0.05% | +21.81% | |
| 23 | MNKD | Mannkind CORP | Stock-Other | 0.86% | — | -11.72% | |
| 24 | BHC | Bausch Health Cos Inc | Stock-Healthcare | 0.86% | — | — | |
| 25 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.83% | +1.50% | -20.28% | |
| 26 | HUM | Humana Inc | Stock-Healthcare | 0.73% | +0.64% | NEW | |
| 27 | DHR | Danaher CORP | Stock-Healthcare | 0.73% | — | -5.94% | |
| 28 | CNC | Centene CORP | Stock-Healthcare | 0.70% | -0.19% | EXIT | |
| 29 | ELV | Elevance Health Inc | Stock-Healthcare | 0.69% | — | +32.80% | |
| 30 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 0.63% | — | — | |
| 31 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 0.62% | — | — | |
| 32 | EOLS | Evolus Inc | Stock-Other | 0.50% | — | -21.13% | |
| 33 | BHVN | Biohaven Ltd. | Stock-Other | 0.45% | +0.40% | NEW | |
| 34 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.44% | -0.54% | -17.26% | |
| 35 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.44% | — | +5.91% | |
| 36 | BKD | Brookdale Senior Living Inc | Stock-Other | 0.40% | +0.27% | -44.32% | |
| 37 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.35% | — | -6.83% | |
| 38 | FNAUSD | Paragon 28 Inc | Stock-Other | 0.34% | — | — | |
| 39 | GOSS | Gossamer Bio Inc | Stock-Other | 0.34% | — | -9.22% | |
| 40 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.32% | — | -9.90% | |
| 41 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.32% | — | +11.24% | |
| 42 | AVTR | Avantor Inc | Stock-Healthcare | 0.30% | -1.23% | EXIT | |
| 43 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.28% | -0.56% | -53.55% | |
| 44 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.27% | -0.40% | EXIT | |
| 45 | KURA | Kura Oncology Inc | Stock-Other | 0.26% | — | +166.05% | |
| 46 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.25% | +0.73% | -42.07% | |
| 47 | ✓ | Merus N V | Stock-Other | 0.23% | — | +2.68% | |
| 48 | STAA | Staar Surgical Co | Stock-Other | 0.23% | — | — | |
| 49 | PBYI | Puma Biotechnology Inc | Stock-Other | 0.23% | — | -2.65% | |
| 50 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.22% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GSK | Gsk Plc-spon Adr | +2.2% | +16.99% | Add |
| 2 | CYH | Community Health Systems Inc | +1.8% | +9.19% | Add |
| 3 | ZIMV | Zimvie Inc | +1.3% | +169.75% | Add |
| 4 | SPY | Ss Spdr S&p 500 ETF Trust-us | +1.2% | +94.81% | Add |
| 5 | VERA | Vera Therapeutics Inc | +1.2% | +0.34% | Add |
| 6 | TECH | Bio-techne CORP | +1% | +22.20% | Add |
| 7 | RVTY | Revvity Inc | +0.9% | +4.01% | Add |
| 8 | BHC | Bausch Health Cos Inc | +0.9% | NEW | New buy |
| 9 | FTRE | Fortrea Holdings Inc | +0.6% | NEW | New buy |
| 10 | ITCIEUR | Intra-cellular Therapies Inc | +0.6% | NEW | New buy |
| 11 | HCA | Hca Healthcare Inc | +0.6% | -4.72% | Trim |
| 12 | VRDN | Viridian Therapeutics Inc | +0.6% | +21.81% | Add |
| 13 | BHVN | Biohaven Ltd. | +0.5% | NEW | New buy |
| 14 | VTRS | Viatris Inc | +0.4% | +29.87% | Add |
| 15 | FNAUSD | Paragon 28 Inc | +0.3% | NEW | New buy |
| 16 | SNDX | Syndax Pharmaceuticals Inc | +0.3% | +13.61% | Add |
| 17 | STAA | Staar Surgical Co | +0.2% | NEW | New buy |
| 18 | ZLAB | Zai Lab Ltd-adr | +0.2% | NEW | New buy |
| 19 | ZBIO | Zenas Biopharma Inc | +0.2% | NEW | New buy |
| 20 | TVTX | Travere Therapeutics Inc | +0.2% | -20.28% | Trim |
| 21 | MRVI | Maravai Lifesciences Hldgs-a | +0.2% | NEW | New buy |
| 22 | PTGX | Protagonist Therapeutics Inc | +0.2% | -11.99% | Trim |
| 23 | CNC | Centene CORP | +0.2% | +16.52% | Add |
| 24 | KURA | Kura Oncology Inc | +0.2% | +166.05% | Add |
| 25 | ELV | Elevance Health Inc | +0.2% | +32.80% | Add |
| 26 | INSM | Insmed Inc | +0.2% | -5.73% | Trim |
| 27 | AVTR | Avantor Inc | +0.1% | +34.27% | Add |
| 28 | MREO | Mereo Biopharma Group Pl-adr | +0.1% | +56.78% | Add |
| 29 | STRO | Sutro Biopharma, Inc. | +0.1% | +5.91% | Add |
| 30 | EOLS | Evolus Inc | +0.1% | -21.13% | Trim |
| 31 | ✓ | +0.1% | NEW | New buy | |
| 32 | MNKD | Mannkind CORP | +0.1% | -11.72% | Trim |
| 33 | IQV | Iqvia Holdings Inc | 0% | +7.88% | Add |
| 34 | DHR | Danaher CORP | 0% | -5.94% | Trim |
| 35 | TSVT* | 2seventy Bio Inc | 0% | -9.90% | Trim |
| 36 | XOMA | Xoma Royalty Corporation | 0% | +2.59% | Add |
| 37 | KPTIEUR | Karyopharm Therapeutics Inc | 0% | +11.24% | Add |
| 38 | ABSI | Absci CORP | — | -16.17% | Trim |
| 39 | ICLR | ICON Public Limited Company | — | +8.12% | Add |
| 40 | GOSS | Gossamer Bio Inc | — | -9.22% | Trim |
| 41 | ACIU | AC Immune SA | — | — | Unchanged |
| 42 | RGEN | Repligen CORP | 0% | -15.80% | Trim |
| 43 | ✓ | Affimed N V | 0% | — | Unchanged |
| 44 | MCRB1EUR | Seres Therapeutics Inc | 0% | EXIT | Sold out |
| 45 | IFRX | InflaRx N.V. | 0% | +3.50% | Add |
| 46 | STOK | Stoke Therapeutics Inc | 0% | -15.13% | Trim |
| 47 | TRML | Tourmaline Bio Inc | 0% | -58.80% | Trim |
| 48 | GTHXEUR | G1 Therapeutics Inc | 0% | EXIT | Sold out |
| 49 | ✓ | Merus N V | 0% | +2.68% | Add |
| 50 | AUTL | Autolus Therapeutics PLC | -0.1% | -33.45% | Trim |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 67 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GSK, QQQ, NTRA) accounted for 29.5% of total reported equity market value during Q3 2024.
Top New Position Initiated
BHC
市值: $12.5M
Top Position Liquidated / Trimmed
NVO
前期市值: $21.0M
During Q3 2024, Eversept Partners, LP's top holdings by market value included GSK (11.4%)、QQQ (8.3%)、NTRA (7.6%). The largest single position, GSK, represented 11.4% of total portfolio value.
In Q3 2024, Eversept Partners, LP made 82 total portfolio adjustments, initiating 10 new buys, adding to 23 positions, trimming 32 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.